Investor Presentaiton

ENHERTU DESTINY-Breast04 data ASCO 2022 Highlights (Plenary Session) PFS in patients with HR+/HER2 low BC 49% reduction in the risk of disease progression or death versus chemo, mPFS of 10.1m compared to 5.4m with chemo PFS (HR+) 100 Hazard ratio: 0.51 95% CI, 0.40-0.64 P < 0.0001 PFS in all patients with HR+ or HR-/HER2 low BC ■50% reduction in the risk of disease progression or death versus chemo, mPFS of 9.9m compared to 5.1m with chemo PFS (All patients) 100 80 Hazard ratio: 0.50 95% CI, 0.40-0.63 P < 0.0001 Progression-Free Survival Probability (%) 20 40 60 80 TPC A 4.7 mo T-DXd mPFS: 10.1 mo mPFS: 5.4 mo 4+1 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Months Progression-Free Survival Probability (%) 60 A 4.8 mo 40 20 TPC mPFS: 5.1 mo T-DXd mPFS: 9.9 mo BC: breast cancer, HR: hormone receptor, mPFS: median progression-free survival, PFS: progression-free survival, T-DXd: trastuzumab deruxtecan, TPC: treatment of physician's choice 0 0 1 2 3 4 5 6 8 7 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Months 18 Daiichi-Sankyo

View entire presentation